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Disorders characterized by expansion of an unstable nucleotide repeat account for a number of inherited
neurological diseases. Here, we review examples of unstable repeat disorders that nicely illustrate three of
the major pathogenic mechanisms associated with these diseases: loss of function typically by disrupting
transcription of the mutated gene, RNA toxic gain of function, and protein toxic gain of function. In addition
to providing insight into the mechanisms underlying these devastating neurological disorders, the study of
these unstable microsatellite repeat disorders has provided insight into very basic aspects of neuroscience.Introduction
Some 20 years ago expansion of unstable nucleotide (microsa-
tellite) repeats, notably trinucleotide repeats, was identified
as a novel mutational mechanism underlying certain human
diseases. Over the years, other disease-associated expandable
microsatellite repeats were discovered including additional
trinucleotide repeats as well as unstable tetra-, penta-, hexanu-
cleotide, and longer repeats (Mirkin, 2007). Remarkably many
of the unstable DNA microsatellite repeat disorders manifest
with neurological and neuromuscular symptoms. These include
fragile X syndrome, the most common inherited form of intellec-
tual disability, myotonic dystrophy a common genetic muscular
dystrophy, Huntington’s disease, a group of dominantly inherited
ataxias, and most recently an unstable hexanucleotide repeat
in the C9ORF72 gene as a frequent cause of frontotemporal
dementia/amyotrophic lateral sclerosis (DeJesus-Hernandez
et al., 2011; Renton et al., 2011). While the disorders highlighted
in this review reflect the experiences and interests of the authors,
they also illustrate three key means by which expansion of
unstable microsatellite repeat results in disease (Figure 1); loss
of function typically by disrupting transcription of the mutated
gene (fragile X syndrome, FXS), a RNA toxic gain of function
(fragile X tremor-ataxia syndrome, FXTAS), and a protein toxic
gain of function in two of the polyglutamine diseases (spinocer-
ebellar ataxia type 1, SCA1 and spinal bulbar muscular atrophy,
SBMA). Formore inclusive reviews and those presenting alterna-
tive points of view the reader is referred to several recent and
excellent articles (Williams and Paulson, 2008; La Spada and
Taylor, 2010; Ross and Tabrizi, 2011; Pastore and Temussi,
2012; Renoux and Todd, 2012).
Loss of Function—Fragile X Syndrome
Fragile X syndrome (FXS) is a common inherited form of intel-
lectual disability (ID) frequently associated with autism spectrum
disorder (ASD) (Bhakar et al., 2012; Santoro et al., 2012). The
condition was first reported by Martin and Bell in 1943 as
a then-novel example of ID segregating in an X-linked fashion
(Martin and Bell, 1943). These authors noted what would laterbecome a key feature of the disorder, but at the time seemed
unusual in their pedigree: nonpenetrant carrier males. For years,
other descriptions of such pedigrees were few, until Lubs
described a similar pedigree that had the distinction of segre-
gating a ‘‘marker X chromosome’’ with the disorder (Lubs,
1969). This marker X showed a fragile site, or nonstaining gaps
in the metaphase chromosome, near the end of the long arm
of the X chromosome (Figure 2A). Once it became clear that
this fragile site required specific culture conditions to be visible
(Sutherland, 1977), many other pedigrees were found (Jacobs
et al., 1980). With the addition of these families, the issue of non-
penetrant carrier maleswas rediscovered by Sherman et al., who
found that 20% of males who inherited themutation were normal
and termed them ‘‘normal transmitting males’’ since their
daughters were found to all be carriers (Sherman et al., 1984).
Using a total of 206 pedigrees, Sherman et al. made the remark-
able observation that sibships containing a normal transmitting
male were less likely to have an affectedmale, and such sibships
occurred more frequently in earlier generations, which raised the
portentous notion of alleles of three states: normal, premutated,
and fully mutated (Sherman et al., 1985). Inexplicable in terms of
conventional genetics, this phenomenon became known as the
‘‘Sherman paradox,’’ later linked to the equally mystifying
concept of ‘‘genetic anticipation,’’ where age of onset decreases
or disease severity increases as amutationmoves generationally
through an affected family (Harper, 1989).
Using a variety of emerging methodologies from the nascent
genome project, both the mutation (Heitz et al., 1991; Kremer
et al., 1991; Oberle et al., 1991) and gene (Verkerk et al., 1991)
were identified in 1991. The gene, called fragile Xmental retarda-
tion 1, or FMR1, is located precisely at the fragile site on the X
chromosome and contains a polymorphic CGG repeat in the 50
untranslated region of exon 1. The unstable expansion of this
repeat is the most common cause of FXS and is the archetypal
‘‘dynamic mutation’’ of triplet repeat expansion. FMR1 has four
allelic classes (Figure 2B). Normal alleles contain 5 to 44 repeats,
with the most common normal allele harboring 29 or 30 repeats.
Alleles from patients with FXS, referred to as full mutation alleles,Neuron 77, March 6, 2013 ª2013 Elsevier Inc. 825
Figure 1. Overview of Three Pathogenic
Mechanisms
Pathogenic mechanisms for Fragile X syndrome
(FXS), Fragile X tremor-ataxia syndrome (FXTAS)
and myotonic dystrophy (DM), the polyglutamine
diseases spinocerebellar ataxia type 1 (SCA1) and
spinal bulbar muscular atrophy (SBMA) and
related disorders are presented. These include (1)
loss of function due to block of transcription, (2)
gain of function by a pathogenic RNA, and (3) gain
of function by a protein.
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expanded alleles are derived from premutation alleles that
contain between 54 and 200 repeats. Premutation alleles are
meiotically unstable, particularly when maternally transmitted.
All full mutations are derived from maternal premutations,
whereas male premutation carriers account for the normal
transmitting males noted by Sherman et al. The resolution of
the Sherman paradox came about when the length of the
maternal premutation was recognized as being directly propor-
tional to the risk of expansion into the full mutation range (Fu
et al., 1991). For example, a woman with a premutation of 60–
69 repeats has a 2% chance of the allele expanding beyond
200 repeats, compared to a woman with 90–99 repeats, who
has a 94% risk (Nolin et al., 2011). Finally, the fourth allelic class
is of the intermediate alleles, between 45 and 54 repeats. While
these are essentially normal alleles in that they do not transmit
directly to the full mutation, they are slightly unstable, often
changing by one or two repeats (Zhong et al., 1996). The
CGG repeat of FMR1 is often interrupted by one or more AGG
triplets, and AGG interruptions are known to stabilize the pre-
mutation (Eichler et al., 1994; Kunst and Warren, 1994), with
the interruption pattern recently found to refine the genetic
risk of having an affected child (Nolin et al., 2011; Yrigollen
et al., 2012).
Premutation alleles, although they carry the obvious genetic
risk of having a child with FXS (in females), have recently been
associated with phenotypes that do not resemble FXS. Women
who carry the premutation allele are at 25% risk of primary
ovarian insufficiency, referred to as fragile X-associated prema-
ture ovarian insufficiency, or FXPOI (Conway et al., 1998; Sullivan
et al., 2005). In these carriers, menopause prior to 40 years of
age, and sometimes considerably earlier, has a major impact
on their reproductive futures, as well as their risk for earlier health
sequelae following menopause. While the mechanism behind
FXPOI is poorly understood, the greatest risk appears among
women with premutation alleles in the middle of the premutation
range (Sullivan et al., 2005). Premutation males, on the other
hand, are at substantial risk of fragile X-associated tremor ataxia
syndrome, or FXTAS, covered in detail below.826 Neuron 77, March 6, 2013 ª2013 Elsevier Inc.When the CGG repeat in FMR1
expands into the full mutation range, an
epigenetic trigger occurs, causing wide-
spread methylation of the gene that is
correlated with its loss of function (Pieretti
et al., 1991). This methylation imprint
occurs early in embryogenesis (Malteret al., 1997; Sutcliffe et al., 1992) and leads to histone changes
that reflect the gene silencing (Coffee et al., 1999, 2002). Thus,
the full mutation is a null mutation, and the absence of its en-
coded protein, FMRP, is responsible for the disorder (Meijer
et al., 1994). It should be noted that conventional mutations of
FMR1might disrupt expression by deletion, nonsense, or splice
site mutations, also leading to FXS (Coffee et al., 2008; Grønskov
et al., 2011; Lugenbeel et al., 1995; Wang et al., 1997). There
appears to be a deficit of reported missense mutations of
FMR1, with only a single confirmed pathological amino acid
substitution (I304N); a sequencing screen of males suspected
of FXS without repeat expansion found only one additional
missense mutation (R138Q) (Collins et al., 2010; Feng et al.,
1997a; Reyniers et al., 1996). It is likely that the infrequent clinical
sequencing of FMR1 and the possibility of a subtler phenotype
with such mutations could account for the paucity of missense
mutations.
Since the absence of FMRP results in ID and ASD, there has
been intense research over the past two decades that has
provided substantial insight into the normal function of FMRP
and the molecular consequences of its absence. Indeed, FXS
may well be mechanistically the best understood of all neuro-
developmental disorders today. The human FMR1 gene is
composed of 17 exons with significant alternative splicing (Ash-
ley et al., 1993b; Eichler et al., 1993); accordingly, western blots
reveal multiple FMRP isoforms between 67 and 80 kDa, with iso-
form 7 being the most prominent at 69 kDa (Devys et al., 1993;
Verheij et al., 1993). FMRP is largely cytoplasmic, with perhaps
5% being nuclear (Feng et al., 1997b), and the protein is widely
expressed, although most strongly in neurons and testes.
FMRP contains several domains (Figure 2C) that provide clues
to its function. The protein contains two KH domains and a RGG
box, all associated with RNA binding (Ashley et al., 1993a; Siomi
et al., 1993). Indeed, FMRP is a selective RNA-binding protein
that interacts with perhaps 4% of the mammalian brain mRNAs.
In the brain, the majority of FMRP is associated with translating
ribosomes (Feng et al., 1997b; Khandjian et al., 2004; Stefani
et al., 2004). This associationwith polysomes reflects a key prop-
erty of FMRP as the I304N mutation that causes FXS in human
Figure 2. Key Elements of FXS
(A) The fragile X chromosome. The fragile site
indicated by arrow.
(B) Alleles of FMR1.
(C) Important FMRP features. Nuclear localiza-
tion signal (NLS) and nuclear export signal (NES).
K-homology domain (KH) and arginine-glycine-
glycine box (RGG) indicated. Agent domains are
part of a family of Tudor domains that interact with
certain methylated amino acids. The scale is
amino acid number.
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ciate with polysomes (Feng et al., 1997a; Zang et al., 2009).
In addition to RNA-binding domains, FMRP contains both
a nuclear localization signal and a nuclear export signal, sug-
gesting FMRP shuttles between the nucleus and the cytoplasm
(Bardoni et al., 1997; Eberhart et al., 1996), perhaps binding its
mRNA ligands cotranscriptionally (Kim et al., 2009). A precise
nuclear function of FMRP, if any, is unclear, although in the
extreme N terminus of the protein are two Agenet domains, of
the Tudor-family domains, and these are capable of binding
methylated lysines and arginines (Maurer-Stroh et al., 2003). A
role for FMRP binding to methyl-lysine or methyl-arginine has
yet to be elucidated.
RNA selectivity requires recognition elements embedded
within the messages for the protein to recognize; however, the
precise nature of the RNA recognition element remains contro-
versial. Initial data on the analysis of FMRP-immunoprecipitated
mRNAs and in vitro selected RNA ligands indicated RNA struc-
ture rather than precise sequence is important (Brown et al.,
2001; Darnell et al., 2001). Stem-G-quartet loops appeared to
interact with the RGG box domain, while a ‘‘kissing complex’’
RNA structure bound to the KH2 domain (Darnell et al., 2005).
The later interaction seemed particularly compelling as kissing
complex RNA could compete with natural RNA ligands, running
FMRP off ribosomes. Further support for structural-based
elements came from the identification of mRNAs containing
a stem-loop motif called SoSLIP and U-rich structures inter-
acting with FMRP (Bechara et al., 2009; Chen et al., 2003a;
Fa¨hling et al., 2009). However, with the advent of much more
robust protein RNA cross-linking strategies to identify mRNANeurontargets of FMRP, the structural hypoth-
esis appeared too simplistic. Using
HITS-CLIP, Darnell et al. (2011) identified
842 robust mRNA targets. Although there
was significant overlap with earlier immu-
noprecipitated mRNAs thought to
interact via stem-G-quartets, there was
no enrichment of such structures in the
842 messages compared to nontarget
messages. More recently, Ascano et al.
(2012), using a variation of the HITS-
CLIP strategy, identified another set of
mRNAs bound to FMRP with unclear
overlap with earlier studies. Here, a short
sequence motif was identified in the
targets consisting of multiple (18 per
transcript) occurrences of WGGA- and ACUK-containing
elements (W = A/U and K = G/U) throughout the coding
sequence and 30UTR. The relationship, if any, between the
WGGA/ACUK elements and earlier identified RNA structures
remains to be clarified.
The most widely accepted function of FMRP is as a translation
regulator (Bagni et al., 2012; Bhakar et al., 2012; Santoro et al.,
2012), particularly at the synapse where it was shown that
FMRP itself was locally synthesized following group I metabo-
tropic glutamate receptor agonists (Greenough et al., 2001).
One highly regarded mechanism is that FMRP stalls ribosomes
on target messages (Ceman et al., 2003; Darnell et al., 2011).
Thus, FMRP is considered a negative regulator of translation.
In vitro FMRP can suppress translation of target messages in
rabbit reticulolysate or Xenopus oocytes (Laggerbauer et al.,
2001). Direct measurement of total protein synthesis in the
Fmr1 knockout mouse shows excess translation in the brain,
consistent with the loss of a translation repressor (Do¨len et al.,
2007; Muddashetty et al., 2007). Using 14C- leucine to determine
regional rates of cerebral protein synthesis, Qin et al. (2005)
demonstrated enhanced synthesis in vivo in the knockoutmouse
brain. Finally, in a key study linking FMRP loss and synaptic
defects, Huber et al. (2001, 2002) showed that metabotropic
glutamate receptor (mGluR)-dependent long-term depression
(LTD), previously found to require local protein synthesis, was
exaggerated and independent of new protein synthesis in the
Fmr1 knockout mouse. Not only would this be consistent with
a loss of a negative regulator of translation but also suggests
an uncoupling of synaptic protein synthesis machinery from
synaptic output. Similar to the exaggerated LTD in these studies,77, March 6, 2013 ª2013 Elsevier Inc. 827
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oxazole propionic acid (AMPA) receptors is directly proportional
to FMRP loss in rat hippocampal neurons or cultured hippo-
campal neurons of the Fmr1 knockout mouse (Henderson
et al., 2012; Nakamoto et al., 2007). Thus, FMRP loss leads to
excess local translation of its target mRNAs, which in turn leads
to a decrease in synaptic strength and dendritic spine dysmor-
phogenesis (Bagni and Greenough, 2005). It should be noted,
however, that for a small minority of mRNA, FMRP appears to
be required for translation (Bechara et al., 2009; Gross et al.,
2011).
If FMRP normally functions as a negative regulator of transla-
tion, it must be regulated to allow translation of its targets in the
appropriate context. Phosphorylation of FMRP at serine 500
(serine 499 in the mouse) is one attractive model of regulation
that has been put forward (Ceman et al., 2003). Under thismodel,
phospho-FMRP stalls ribosomes on target mRNA in or near the
dendritic spine. Following mGluR stimulation, FMRP is instantly
dephosphorylated by PP2A, releasing the translational repres-
sion and allowing a burst of local protein synthesis that dynam-
ically modulates synaptic strength (Narayanan et al., 2007).
Within minutes, FMRP is then found phosphorylated, with
S6K1 proposed as the responsible kinase (Narayanan et al.,
2008). Although it is possible the dephosphorylated FMRP is re-
phosphorylated by S6K1, recent evidence points to dephos-
phorylated FMRP being rapidly ubiquitinated and degraded by
the ubiquitin proteasome system, and the emergence of
phospho-FMRP reflects phosphorylation of newly synthesized
FMRP (Nalavadi et al., 2012).
Themechanism by which FMRP regulates translation is some-
what controversial. As mentioned earlier, ribosomal stalling is
a popular candidate, with such stalling mediated by the micro-
RNA pathway via phosphorylation (Bassell and Warren, 2008).
FMRP is found to interact with the RNA-induced silencing
complex (RISC) and with microRNAs themselves, indicating
FMRP may use the ability of the RISC to stall ribosomes (Bolduc
et al., 2008; Caudy et al., 2002; Ishizuka et al., 2002; Jin et al.,
2004). Indeed, Muddashetty et al. (2011) have shown that the
30UTR of PSD95, a mRNA target of FMRP, contains a G-rich
sequence required for FMRP binding that is also the target of
miR-125a. Bidirectional control of PSD-95 expression depends
on miR-125a and FMRP phosphorylation status; FMRP phos-
phorylation promotes the formation of an AGO2-miR-125a
inhibitory complex on PSD-95 mRNA, whereas mGluR signaling
of translation requires FMRP dephosphorylation and release of
AGO2 from the mRNA. These findings reveal a mechanism
whereby FMRP phosphorylation provides a reversible activity-
dependent switch to selectively regulate mRNA translation at
synapses. In contrast to this mechanism, it is known that non-
polysomal FMRP can repress translation by inhibiting cap-
dependent initiation via interaction with the eIF4E-binding
protein, CYFIP1 (Napoli et al., 2008). Moreover, haploinsuffi-
ciency of CYFIP1 in mice results in increased LTD and both
biochemical and behavioral phenotypes reminiscent of the
Fmr1 knockout mouse, which is consistent with a reduction in
translational repression (Bozdagi et al., 2012). Though the signif-
icance of this mechanism has been questioned because the vast
majority of FMRP is associated with ribosomes (Darnell et al.,828 Neuron 77, March 6, 2013 ª2013 Elsevier Inc.2011), it may be that both mechanisms are correct, depending
upon the cellular context FMRP is in. For example, FMRP may
be repressing translation of target mRNA during their transport
from soma to dendrites by inhibiting cap-dependent initiation.
FMRP is found in a variety of RNA granules, including P bodies
and stress granules, where translational repression is preinitia-
tion or ribosome association (Antar et al., 2004, 2005; De Diego
Otero et al., 2002). Once localized to the synapse, the granule
could release FMRP-bound messages (Krichevsky and Kosik,
2001), either switching then to ribosome stalling or by earlier
conversion to high-density granules which contain stalled ribo-
somes (Kiebler and Bassell, 2006).
Althoughmost studies of FMRP have focused upon a postsyn-
aptic function involving protein translation, a presynaptic role
has recently been illuminated. Deng et al. (2013) have demon-
strated a FMRP-dependent action potential broadening in
hippocampal and cortical pyramidal neurons. Unlike the post-
synaptic function of FMRP, this presynaptic action of FMRP is
translation independent and appears modulated by large
conductance calcium-activated potassium channels (BK chan-
nels) through the interaction of FMRP with the BK channel’s
regulatory b4 subunits.
As our understanding of FMRP function has become more
granular and our view of the consequences of its absence
more finely detailed, new avenues for possible therapeutic inter-
ventions have emerged. Based on the observation of enhanced
protein synthesis-dependent, mGluR5-stimulated LTD in the
Fmr1 knockout mouse (Huber et al., 2002), the ‘‘mGluR theory
of FXS’’ was born (Bear et al., 2004). This theory proposes that
the signaling cascade that triggers local protein synthesis by
mGluR stimulation is regulated by FMRP and in its absence
runs unchecked. Therefore, reduction of the initial stimulation,
using mGluR5 antagonists, may reduce the constitutive transla-
tion to achieve some level of correction. In the years since the
theory was first published, compelling support for it has come
from a remarkable series of studies that used both pharmaco-
logic and genetic means to reduce mGluR signaling in a variety
of organisms (detailed in Bhakar et al., 2012; Krueger and
Bear, 2011). Biochemical and behavioral studies in the mouse
have provided enough preclinical evidence that reducing
mGluR5 can correct FXS-like phenotypes to launch clinical trials.
Several such studies are underway with AFQ056 (Novartis),
R04917523 (Hoffman-La Roche), and STX107 (Seaside), all
mGluR5 antagonists (see clinicaltrials.gov for the latest). One
study published thus far using AFQ056 suggests improvements
in inappropriate speech, stereotypic behavior, and hyperactivity
in FXS males with the full mutation (Jacquemont et al., 2011).
Although this was a small study and efficacy emerged only after
post hoc analysis, it is encouraging that ongoing trials with all the
antagonists may produce some measure of improvement.
An alternative approach to dampen the exaggerated glutami-
nergic signaling, is to pharmacologically activate the Y-amino-
butyric (GABA) receptors, which will stimulate the inhibitory
pathway (Hampson et al., 2011). Support for this approach
came from a small molecule screen to reverse glutamate-
induced toxicity in FMRP-deficient Drosophila (Chang et al.,
2008). The top three hits in the screen of 2,000 compounds all
implicated the GABAergic pathway, and subsequent studies
Neuron
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and behavioral abnormalities in the fly FXS model. These data
validated earlier studies indicating the GABAergic pathway
was downregulated in FXS (D’Hulst et al., 2006). Although the
GABA(A) pathway is clearly compromised in the Fmr1 knockout
mouse (Curia et al., 2009; D’Hulst et al., 2009; Gantois et al.,
2006), there is evidence that stimulation of the GABA(B) receptor
could reverse seizure susceptibility in the mouse model (Pacey
et al., 2009). Recently, a comprehensive preclinical study in
the mouse validated the GABA(B) agonist STX209 (arbaclofen,
Seaside) as capable of reversing many phenotypes in the
knockout mouse model (Henderson et al., 2012). In a random-
ized, placebo-controlled crossover trial of 63 subjects with
FXS, STX209 appeared to have a significant beneficial treatment
effect on measures of behavior (Berry-Kravis et al., 2012),
although this too was a post hoc finding. Several ongoing trials
with STX209 are active or recruiting (www.clinicaltrials.gov).
Because of its history, FXS has long been considered a model
for biomedical investigation of idiopathic autism spectrum
disorder, but there is now a growing body of evidence that
FMRP may be intimately involved in the signaling pathways
and circuits potentially disrupted in ASD. First, proteins involved
in syndromic ASD, such as PTEN, TSC1, and TSC2, as well as
proteins mutated in rare nonsyndromic ASD, such as NLGN4,
NRXN1, and SHANK3, all modulate postsynaptic signaling,
and the former are all key glutamatergic signaling elements
with FMRP in the mTOR pathway regulating activity-dependent
protein synthesis (Zoghbi and Bear, 2012). Second, although
different approaches were used to identify the mRNA targets
of FMRP, all the contemporary studies show a statistically
significant enrichment of candidate autism susceptibility gene
messages binding to FMRP (Ascano et al., 2012; Darnell et al.,
2011). Finally, de novo gene disruptions found in ASD by exome
sequencing reveal a disproportionate number of genes whose
mRNA are known FMRP targets (Iossifov et al., 2012). This gives
us hope that, while the etiology of ASD may be heterogeneous,
many of the susceptibility loci could interact in a common
pathway. Another hopeful possibility is that therapeutic strate-
gies now in clinical trials for FXS may prove beneficial for
idiopathic ASD.
Two Polyglutamine Diseases—SBMA and SCA1
Among the first trinucleotide microsatellite repeat disorders
identified was the CAG repeat expansion underlying spinal
and bulbar muscular atrophy (SBMA) or Kennedy’s disease
(La Spada et al., 1991). This discovery was soon followed by
the elucidation of a similar mutation as the basis of a group of
disorders now known as the polyglutamine neurodegenerative
diseases. Along with SBMA, the polyglutamine diseases include
Huntington disease (HD), dentatorubral-pallidoluysian atrophy
(DRPLA), and six spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7,
and 17 (Orr and Zoghbi, 2007). As a group, these nine diseases
are one of the more common forms of inherited neurodegenera-
tion (Figure 1).
With elucidation of the polyglutamine neurodegenerative
diseases, it was apparent that the only feature common among
the affected proteins was the polyglutamine tract itself. In most
cases the polyglutamine tract was found in novel proteins whosefunction was unknown. Only in three diseases did the polyglut-
amine expansion occur in a previously known protein—SBMA
in the androgen receptor, a ligand-dependent nuclear hormone
receptor transcription factor; SCA6 and the a1A subunit, the
transmembrane pore-forming subunit, of the P/Q-type or
CaV2.1 voltage-gated calcium channel; SCA17 in the TATA-
binding protein, a general transcription factor that plays an
important role in initiation of transcription for all three eukaryotic
polymerases. So how could the same mutation, a polyglutamine
expansion in most cases to around 40 glutamines or more, in
nine different proteins result in nine different diseases?
Although it is generally regarded that a major aspect of
polyglutamine pathogenesis is a polyglutamine-induced toxic
gain-of-function activity on host proteins, the more detailed
molecular basis of these disorders remains controversial.
Perhaps themost seminal unresolved issue is the extent towhich
the pathogenic mechanism is due to a direct toxicity of an
expanded polyglutamine tract and, thus, common among the
diseases. One at least initially widely held hypothesis whereby
pathogenesis is driven by the polyglutamine tract, is one where
disease is caused by the accumulation of aggregates containing
a misfolded form of the affected protein (Pastore and Temussi,
2012). This hypothesis has its roots in the observation that a
pathological hallmark of many of these diseases is the presence
of intracellular inclusions containing the mutant polyglutamine
protein. The ability of an expanded polyglutamine stretch to pro-
mote protein aggregation and subsequent disruption of cellular
protein homeostasis in some model systems provides experi-
mental evidence in support of a misfolded protein/aggregation
hypothesis (Powers et al., 2009). At the core of this mechanism
is the concept that it is a misfolded, nonnative conformation of
the polyglutamine protein, induced by an expanded polyglut-
amine tract, which initiates the pathogenic process. However,
there is evidence questioning whether the large aggregates/
inclusions of mutant protein are directly pathogenic (Klement
et al., 1998; Saudou et al., 1998; Cummings et al., 1999; Arrasate
et al., 2004). In fact, some studies suggest these inclusions likely
have, at least early in disease progression, a protective role
perhaps by sequestering mutant protein (Saudou et al., 1998;
Watase et al., 2002). In the case of Huntington’s disease, con-
siderable evidence using a variety of experimental approaches
supports a model of pathogenesis where release by proteolytic
cleavage of a toxic polyglutamine fragment from Huntingtin is
key (reviewed by Ross and Tabrizi, 2011).
An additional hypothesis poses that a normal function and,
thereby, native conformation/interactions underlie the mecha-
nism of pathogenesis (Riley and Orr, 2006). Key in the develop-
ment of this idea were findings that residues/regions outside of
the polyglutamine tract have a crucial role in pathogenesis and
in some instances the demonstration that polyglutamine expan-
sion in itself is not sufficient to cause disease (Emamian et al.,
2003; Gu et al., 2009; Humbert et al., 2002; Katsuno et al.,
2002; Klement et al., 1998; Takeyama et al., 2002). These resi-
dues function to modulate the normal biology of the polyglut-
amine protein and presumably pathogenesis by impacting its
normal subcellular location, degradation, and interaction with
other cellular molecules. Of the polyglutamine disorders, spino-
bulbar muscular atrophy (SBMA) and spinocerebellar ataxia typeNeuron 77, March 6, 2013 ª2013 Elsevier Inc. 829
Figure 3. Key Structural Features of the
Androgen Receptor (SBMA) and Ataxin-1
(SCA1)
(A) Schematic depiction of the androgen receptor
protein. Features depicted are (Q)n, polymorphic
polyglutamine tract; NTD, N-terminal domain;
DBD, DNA binding domain; NLS, nuclear location
signal; LBD, ligand binding domain; AF1, tran-
scription activation function 1 region; AF2, tran-
scription activation function 2 region.
(B) Diagram of the Ataxin-1 protein. Features
depicted are: (Q)n, polymorphic polyglutamine
tract; AXH, ataxin-1/HBP1 homology domain;
NLS, nuclear location signal (expanded to indicate
location of S776, serine 776, 14-3-3 LM, 14-3-3
binding site; ULM, binding site for RBM17 and
U2AF65; SAR, self-association region; RNA bind-
ing region; CIC, binding region for Capicua.
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conformation being tied to pathogenesis is well demonstrated
(Kratter and Finkbeiner, 2010).
Among the polyglutamine disorders, SBMA in many ways
is the prototype in linking normal function to pathogenesis.
SBMA, also known as Kennedy’s disease, is a progressive
late-onset disease that consists of motor neuron degeneration
in the brainstem and spinal cord (Kennedy et al., 1968). As
mentioned above, SBMA is due to expansion of a CAG repeat
in the androgen receptor (AR) gene located on the X chromo-
some (La Spada et al., 1991). Importantly, SBMA affects only
males. Even females homozygous for ARswith an expanded pol-
yglutamine fail to develop the neurodegeneration and neurolog-
ical symptoms seen in affected males, suggesting that perhaps
high levels of circulating androgen have a role in pathogenesis
(Schmidt et al., 2002). Direct evidence in support of this concept
was obtained with the development of transgenic mouse and
Drosophila models in which only males with an expanded poly-
glutamine AR gene developed disease (Katsuno et al., 2002:
Takeyama et al., 2002). Removal of testosterone from young
mutant transgenic male mice blocked development of disease
(Katsuno et al., 2002), while in older mutant males castration
restored normal function (Chevalier-Larsen et al., 2004). Corre-
spondingly, female mice carrying a mutant AR gene developed
disease upon administration of testosterone (Katsuno et al.,
2002). This same androgen-dependent neurodegeneration is
seen in Drosophila expressing a polyglutamine expanded AR
(Takeyama et al., 2002). Although Drosophila lacks an ortholog
to human AR, the nuclear hormone transactivation pathways
are well conserved (King-Jones and Thummel, 2005; Takeyama
et al., 2004).830 Neuron 77, March 6, 2013 ª2013 Elsevier Inc.Unlike the polyglutamine diseases
where little was known about the function
of the affected protein, the normal
structure/function of AR is well character-
ized. The AR consists of several func-
tional elements/domains (Figure 3). The
AR aminoterminal region contains, along
with the polyglutamine tract, two
so-called activation functions AF-1 and
AF-5. In absence of ligand, androgenreceptor resides in the cytoplasm in an inactive form in a complex
with a chaperone. Upon binding androgen, the hormone-
receptor complex translocates to the nucleus, binds to DNA at
specific recognition sites upstream of its target genes. Expres-
sion or repression of these genes occurs through the interaction
of two coregulator regions of AR, AF-1 and AF-2 (Figure 3),
with other transcription factors. In a recent and elegant study,
Nedelsky and colleagues also showed that ligand binding was
necessary for expanded polyglutamine AR to cause degenera-
tion ofDrosophila adult photoreceptors and larval motor neurons
(Nedelsky et al., 2010). This study further demonstrated that in
order for mutant AR to cause degeneration, it had to translocate
to the nucleus and bind to DNA. It was shown that one of the
interaction regions of AR, the AF-2 transactivation domain, is
required for toxicity. A genetic screen revealed that several
known AF-2 interacting proteins are modifiers of mutant AR
induced degeneration. These results show that the mutant
AR pathogenic pathway induced by expansion of the polyglut-
amine tract overlaps considerably with the normal AR-ligand
binding pathway. Nedelsky et al. speculated that is an enhance-
ment of a yet to be identified aspect of normal AR function,
involving the AF-2 transduction domain, that causes neurode-
generation. The observation that Drosophila overexpressing
wild-type AR show signs of disease provides additional support
to a native AR function being critical for pathogenesis (Nedelsky
et al., 2010).
Recently, expression of polyglutamine expanded AR in a
mouse model of SBMA was shown to upregulate the gene en-
coding calcitonin gene-related peptide a (CGRP1) (Minamiyama
et al., 2012). CGRP1 was found to be upregulated in motor
neurons of patients with SBMA. Importantly, mutant AR
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altered regulation of transcription being key to the pathogenic
actions of mutant AR. Minamiyama et al. (2012) further reported
that the toxic effects of increasedCGRP1 expression were linked
to the activation of c-Jun N-terminal kinase (JNK). Pharmacolog-
ical and genetic inactivation of CGRP1 reduced neurodegenera-
tion in a mouse model of SBMA. Together these results provide
compelling evidence that stimulation of CGRP1 transcription and
subsequently activation of the JNK pathway by mutant AR is
crucial to SBMA pathogenesis.
Linkage of SCA1 to the HLA complex on the shortarm of chro-
mosome 6 was seminal to isolating the gene (Yakura et al., 1974;
Nino et al., 1980; Morton et al., 1980). An equally critical finding
was the report in 1950 of genetic anticipation (Schut, 1950) that
subsequently was shown to have a form of SCA in linkage with
the HLA complex (Haines et al., 1984). In contrast to SBMA,
spinocerebellar ataxia type 1 (SCA1) is an example of a dis-
order where the host protein, Ataxin-1 (ATXN1), is novel and
whose function was unknown when the disease-causing muta-
tion was identified. Subsequent to cloning the SCA1 gene
(Orr et al., 1993), studies identified several functional/structural
motifs in ATXN1 (Figure 3).
These include the AXH domain that folds into an OB-fold form-
ing both a putative RNA-binding and a protein-protein interac-
tion surface (Chen et al., 2004), a nuclear localization signal
(NLS) (Klement et al., 1998) that overlaps with or is immediately
adjacent to a 14-3-3 binding site (Chen et al., 2003b) and a
UHM ligand motif (ULM) present in proteins associated with
RNA splicing (de Chiara et al., 2009). ATXN1 interacts with
a variety of nuclear components including RNA (Yue et al.,
2001; Irwin et al., 2005), several regulators of transcription,
SMRT (Tsai et al., 2004), Capicua (Lam et al., 2006), Gfi-1 (Tsuda
et al., 2005), and the Rora/Tip60 complex (Serra et al., 2006;
Gehrking et al., 2011) and proteins involved in RNA processing
such as the RNA splicing factors RBM17 (Lim et al., 2008) and
U2AF65 (de Chiara et al., 2009), and p80 coilin involved in the
assembly of U snRNPs (Hong et al., 2003).
The ATXN1/RORa/Tip60 interaction may have implications for
there being a relationship between Purkinje cell development
and SCA1-mediated degeneration later on in adults. First of all,
conditional SCA1 mice were used to demonstrate that a com-
promise in early Purkinje cell development impacts severity
of mutant ATXN1-mediated Purkinje cell degeneration in adult
mice (Serra et al., 2006). SCA1 mice that express mutant
ATXN1 protein after the first three weeks appeared normal with
respect to behavior and cerebellar morphology out past one
year of age. In contrast, SCA1mice with the transgene on during
early postnatal development developed ataxia and Purkinje cell
degeneration as adults. Mechanistic insight for this finding
came by comparing altered cerebellar gene expression in
SCA1 mice with the mouse cerebellar mutant known as stag-
gerer, having an intragenic deletion in the retinoic acid-related
orphan receptor a (RORa) gene (Hamilton et al., 1996). This
comparison yielded an extensive overlap of RORa-regulated
target genes. In addition, there is a reduction in the amount of
RORa protein in Purkinje cells of SCA1 mice. As assessed
by coimmunoprecipitation from cerebellar lysates, RORa and
ATXN1 interact. Yet, these proteins do not interact directlyin vitro. Rather ATXN1 seems to interact directly the RORa coac-
tivator Tip60 (Serra et al., 2006; Gehrking et al., 2011).
In agreement with an ATXN1 nuclear function being critical for
pathogenesis is the finding that a single amino acid substitution
in the NLS of ATXN1 dramatically reduces translocation of the
protein to the nucleus of murine cerebellar Purkinje cells. This
substitution prevents ATXN1 with an expanded polyglutamine
tract from causing disease (Klement et al., 1998). While wild-
type ATXN1 shuttles between the cytoplasm and nucleus,
ATXN1 with an expanded polyglutamine tract is unable to be ex-
ported from the nucleus and, thus, is retained in the nucleus
(Irwin et al., 2005). Therefore, pathogenesis of both SBMA and
SCA1 stem from altered events in the nucleus. What about the
other polyglutamine disorders? Might alterations in the regula-
tion of gene expression underlie pathogenesis of these diseases
as a group? There are three points that argue in favor of such an
idea. First, many regulators of transcription contain glutamine-
rich activation domains that are typical of an extensive family
of highly conserved transcriptional activators. These gluta-
mine-rich activation domains are an important class of protein-
protein interacting motifs that enable transcription factors to
interact with one another and thus regulate gene expression.
Second, are the observations that transcriptional alterations
appear early in disease progression for the various polyglut-
amine diseases and that mutant polyglutamine proteins interfere
with a large number of transcription factors (Sugars and
Rubinsztein, 2003). The one outlier in a nuclear-mediated mech-
anism for polyglutamine pathogenesis is SCA6 where the muta-
tion occurs in theCACNA1A gene that encodes the a1 subunit of
a voltage-gated calcium channel (Zhuchenko et al., 1997), indi-
cating that an alteration in ion channel function underlies
SCA6. However, Christopher Gomez and colleagues recently
obtained compelling evidence that this is not the case (X. Du, J.
Wang, H. Zhu, L. Rinaldo, Y. Hu, K.-M. Lamar, A.C. Palmenberg,
C. Hansel, and C.M. Gomez, personal communication). They
found that CACNA1A produces a bicistronic mRNA bearing
a cryptic internal ribosomal entry site with the first cistron
encoding the a1A subunit and the second cistron encoding
a novel transcription factor, designated a1ACT. a1ACT contains
the polyglutamine tract and regulates expression of a set of
genes involved in neural and Purkinje cell development. a1ACT
carrying an expanded polyglutamine tract, lacks transcription
factor function, causes cell death in culture, and leads to ataxia
and cerebellar atrophy in transgenic mice.
Studies reveal that the majority of soluble ATXN1 in the
nucleus is normally associated with other proteins in large
(approximately 1.8 MDa) multimeric complexes (Lam et al.,
2006; Lim et al., 2008). In regards to pathogenesis, are the
complexes ATXN1 forms with the transcription factor Capicua
(Cic) and the splicing factor RBM17. Along with ATXN1, both
Cic and RBM17 are highly expressed in the nuclei of Purkinje
cells where polyglutamine ATXN1 is believed to do the most
harm. The effect polyglutamine expansion has on ATXN1’s inter-
action with and alteration of Cic function is multifaceted. Cic is
a transcriptional repressor that contains a Sox-like high mobility
group (HMG) box. Cic binds directly to the AXHdomain of ATXN1
(Lam et al., 2006). In a transfected cell-based transcriptional
assay, wild-type ATXN1 synergizes with Cic to repressNeuron 77, March 6, 2013 ª2013 Elsevier Inc. 831
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repression of transcription is compromised with polyglutamine-
expanded ATXN1, suggesting that polyglutamine-expanded
ATXN1 might cause a loss of Cic transcriptional function (i.e.,
derepression). A more recent study indicates that for some Cic
gene targets expanded ATXN1 causes a loss of function while
at other targets polyglutamine-expanded ATXN1 enhances
Cic binding inducing a state of hyper-repression (Fryer et al.,
2011). This study postulated that it is the hyper-repressive
effects of expanded polyglutamine ATXN1 that are toxic. In
support of this idea is the demonstration that in a mouse model
of SCA1 a reduction in Cic either genetically or, intriguingly, by
exercise dampened toxic gain of function of polyglutamine
expanded ATXN1.
In another study, genes with altered expression due to ATXN1
and corepressors with which it binds were identified using
chromatin immunopreciptiation along with functional transcrip-
tional read-out assays (Cvetanovic et al., 2011). One such
gene encoding the angiogenic/trophic factor VEGF was identi-
fied as a gene repressed bymutant ATXN1. Importantly, restora-
tion of VEGF expression either genetically or pharmacologically
dampens mutant ATXN1-induced pathology. These results
support the notion that transcriptional deficits play a role in
SCA1 pathogenesis.
In the case of the interaction of ATXN1 with the splicing
factor RBM17, polyglutamine expansion and the amino acid at
position 776 affect complex formation (Lim et al., 2008). Expan-
sion of the polyglutamine tract in ATXN1 enhances its interaction
with RBM17. Normally ATXN1 has a serine at position 776,
which is one of seven endogenous sites of phosphorylation in
ATXN1 (Emamian et al., 2003; Huttlin et al., 2010). Evidence
suggests that cyclic AMP-dependent protein kinase (PKA) is
an active ATXN1-S776 kinase in the cerebellum and Purkinje
cells (Jorgensen et al., 2009; Hearst et al., 2010). Placing a phos-
phorylation-resistant alanine at position 776 dramatically
decreases the ability of wild-type or polyglutamine-expanded
ATXN1 to interact with RBM17 (Lim et al., 2008). Conversely, re-
placing serine 776 with a potentially phosphomimicking aspartic
acid increased the ability of wild-type ATXN1 to interact with
RBM17 to a level similar to that seen with ATXN1[82Q]-S776.
Importantly, the extent to which a form of ATXN1 interacts
with RBM17 correlates directly with its ability to cause Purkinje
cell dysfunction and ataxia in vivo. Polyglutamine expanded
ATXN1 with an alanine at position 776 is no longer pathogenic
in vivo (Emamian et al., 2003). On the other hand an aspartic
acid at residue 776, enhances ATXN1 induced pathogenesis
such that even ATXN1 with a wild-type, unexpanded polyglut-
amine becomes pathogenic (Duvick et al., 2010). These results
indicate that the interaction with RBM17 also has a critical role
in pathogenesis.
Phosphorylation of serine 776 (S776) stabilizes ATXN1 and
forms a binding site for the 14-3-3 family of proteins (Chen
et al., 2003b; de Chiara et al., 2009). 14-3-3 proteins are known
to have a critical role in many cell signaling events (Morrison,
2009). In the case of ATXN1, data indicate that upon serine
776 phosphorylation 14-3-3 binds to ATXN1 in the cytoplasm
(Lai et al., 2011). While an aspartic acid at residue 776 stabilizes
ATXN1 and enhances ATXN1’s interaction with RBM17, this832 Neuron 77, March 6, 2013 ª2013 Elsevier Inc.amino acid substitution does not enhance binding of ATXN1
with 14-3-3 (de Chiara et al., 2009; Lai et al., 2011; Menon
et al., 2012). Thus, an aspartic acid at position 776 fails to mimic
all of the effects of phosphorylating serine 776.
Binding of 14-3-3 to ATXN1 was shown to have several
effects. First 14-3-3 binding is associated with a stabilization of
ATXN1 and in the case of polyglutamine expanded ATXN1 an
increase in the formation of nuclear inclusions (Chen et al.,
2003b). A critical question is whether 14-3-3 binding directly or
indirectly stabilizes ATXN1. Recent data suggest that perhaps
the stabilization effect of 14-3-3 binding to ATXN1 is an indirect
effect. 14-3-3 binds to ATXN1 in the cytoplasm blocking the
dephosphorylation of serine 776 (Lai et al., 2011). Since it is
the unphosphorylated form of ATXN1 that seems to be relatively
unstable and more readily degraded, blocking dephosphoryla-
tion of ATXN1 at serine 766 would indirectly stabilize the protein.
Second is the observation that 14-3-3 binding per se is not
required for stabilization of ATXN1. ATXN1-D776, which does
not bind 14-3-3, is as stable in vivo as is ATXN1-S776 (Lai
et al., 2011). In addition to having a role in regulating the dephos-
phorylation of ATXN1 at serine 776 and, thus, the degradation of
ATXN1, 14-3-3 binding also regulates the transport of ATXN1
into the nucleus. Since the 14-3-3 binding site is immediately
adjacent to the NLS in ATXN1, 14-3-3 binding masks the NLS
and blocks entry of ATXN1 into the nucleus (Lai et al., 2011).
Thus, 14-3-3 must be released from ATXN1, presumably by
some regulated process, for ATXN1 to be transported into the
nucleus.
This model places the binding of 14-3-3 to ATXN1 at two steps
that are crucial for polyglutamine expanded ATXN1 to cause
disease – regulation of the level of mutant ATXN1 that directly
correlates with disease severity (Burright et al., 1995; Lorenzetti
et al., 2000; Watase et al., 2002) and entry of ATXN1 into the
nucleus that is required for pathogenicity (Klement et al., 1998).
This raises the question of whether a reduction in 14-3-3 binding
would make disease worse or better. To examine how reducing
14-3-3 levels and thereby its interaction with ATXN1 impacts
disease, knockin Sca1154Q/+ mice were crossed with mice
lacking one allele of 14-3-3ε. 14-3-3ε /+ mice were selected
since 14-3-3ε interacts with ATXN1, is highly conserved, and is
expressed highly in the cerebellum. Sca1154Q/+ animals have
an insertion of a CAG expansion of 154 in the endogenous
Sca1 gene, display many features of human SCA1 including
cerebellar phenotypes such as ataxia, progressive Purkinje cell
degeneration, and noncerebellar phenotypes like weight loss,
and premature death (Watase et al., 2002). Consistent with
14-3-3 having a role in regulating ATXN1 protein levels, a partial
reduction of 14-3-3ε reduced the amount of ATXN1 in the cere-
bellum (Jafar-Nejad et al., 2011). In contrast, inmicewith a partial
loss of 14-3-3ε in the brainstem ATXN1 levels were identical to
those in wild-type mice. Similarly, 14-3-3ε haploinsufficiency
rescued the cerebellar pathology but had no effect on noncere-
bellar phenotypes in Sca1154Q/+ mice. These data argue that 14-
3-3 regulates ATXN1 levels in some regions of the brain, e.g.,
cerebellar Purkinje cells, but not in other regions, e.g., the brain-
stem. Thus, pathogenic pathways may vary among the different
susceptible brain regions, adding another layer of complexity to
SCA1 pathogenesis.
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disease including SCA1, the extent to which disease is reversible
after onset is of importance. To assess reversibility of SCA1,
a conditional mouse model of SCA1 was developed (Zu et al.,
2004). The approach was to use the Pcp2/L7 promoter to drive
a tetracycline-transactivator (Tta) transgene specifically in
Purkinje cells and cross these mice with mice carrying a TRE-
ATXN11[82Q] transgene. Administration of doxycycine (dox),
a tetracycline derivative able to cross the blood brain barrier,
abolishes the Tta/TRE interaction turning off expression of
ATXN1. At the early stage of disease, i.e., 6-week-old mice,
the rotating-rod deficit was reversed completely after 6 weeks
of dox treatment. In addition, Purkinje cell pathology improved
by assessment of molecular layer thickness and dendritic
arborization, although heterotopic Purkinje cells were still
present. When ATXN1 expression is stopped at 12 weeks of
age, a mid-stage disease, animals with the gene off for 4 weeks
continued to have rotating-rod deficits similar to 12 and 16week-
on animals. After longer periods of dox administration, 8 weeks
and 12 weeks, rotating-rod performance improved, but only
partially. Interestingly, this 8-week time point coincided with
the return of mGluR1a glutamate receptors at the Purkinje cell-
parallel fiber synapses, albeit at a lower expression level. There
was recovery of molecular layer thickness and improved arbori-
zation of Purkinje cell dendrites demonstrating that halting
ATXN1[82Q] expression at the time of typical onset of ataxia
prevents the progression of and partially reverses degenerative
changes in Purkinje cells. When dox was given to animals at
32 weeks of age, there was no significant improvement of ataxia,
but there was some improvement of Purkinje cell pathology. At
all disease stages, Purkinje cells rapidly eliminated ATXN1
[82Q]-containing nuclear inclusions upon administration of dox
and cessation of ATXN1 expression. Thus, even at a late stage
of disease Purkinje cells are able to clear ATXN1 protein with
an expanded polyglutamine. Overall, these studies revealed
that Purkinje cell pathology induced by ATXN1with an expanded
polyglutamine could be reversed with cessation of ATXN1
protein synthesis. Interestingly, the capability of Purkinje cells
to recover decreases with increasing age. It remains unclear
whether the age effect on recovery is due to prolonged exposure
to mutant ATXN1 and/or that older neurons in general are less
able to repair damage.
All of the evidence using SCA1 experimental models shows
a direct relationship between disease severity and level of
mutant ATXN1 expression. Identifying pathways or strategies
by which the levels of the disease-causing protein could be
decreased would serve as potential drug targets and or thera-
peutic approaches. An attractiveness of such an approach
is its potential effectiveness irrespective of a lack of clarity
regarding the mechanisms that underlie pathogenesis. Partici-
pation of S776 and its phosphorylation in regulating degradation
of ATXN1 provides one potential therapeutic target for SCA1.
Much effort has gone into and is going into understanding
signaling pathways regulated by protein kinases. Protein kinases
are one of the most active groups under investigation as drug
target owing to their involvement in many pathological con-
ditions. Yet there are considerable challenges facing the thera-
peutic targeting of protein kinases in disorders of the brainlike SCA1 (Chico et al., 2009). Not the least of which is the pene-
tration of the blood-brain barrier and selectively targeting
a multi-functional kinase like PKA. Regardless, identification
of the kinase(s) responsible for ATXN1-S776 phosphoryla-
tion in affected neurons affords an opportunity to elucidate
processes/signals upstream to the kinase that regulate its action
on ATXN1 as wells as elucidation of downstream events
triggered by ATXN1-S776 phosphorylation. Either of which could
result in identification of viable drug targets.
The ability to achieve gene silencing by selectively modulating
RNA function is a genetic approach that offers another potential
means for treating dominantly inherited neurodegenerative
diseases. In the case of SCA1, proof-of-concept for RNA interfer-
ence as a possible treatment approach was demonstrated by
Xia et al. (2004). AAVs expressing shRNAs targeting the ATXN1
[82Q] RNA were injected into the cerebellum of SCA1 mice and
found to improve molecular and motor phenotypes. Since artifi-
cial miRNAs are reported to be less toxic than shRNAs, current
thought would be to use artificial miRNAs for gene silencing
(Boudreau et al., 2009). siRNAs can be delivered directly to
achieve knockdown of a gene of interest. To block their digestion
by nucleases the siRNAs need to be chemically modified. Allele-
specific silencing of mutant Htt in Huntington disease (HD)
mouse models was recently achieved using chemically modified
single stranded siRNAs (Yu et al., 2012; Lima et al., 2012).
An alternative approach for reducing mutant protein synthesis
in the brain is infusion of single-stranded antisense oligonucleo-
tides (ASOs) that guide degradation of target RNAs. Recently,
infusion into the CSF of ASOs to the another polyglutamine
protein, huntingtin, was shown to provide a reversal of disease
phenotypes in a Huntington’s disease mouse model (Kordasie-
wicz et al., 2012). An exciting finding of this study was that a
transient ASO infusion and reduction of huntingtin yielded
a sustained reversal of disease symptoms, suggesting that
a sustained therapeutic efficacy may not require continuous
treatment.
Toxic RNA—Fragile X Tremor/Ataxia and Myotonic
Muscular Dystrophy
It was ten years after the discovery of the expanded CGG triplet
repeat that caused fragile X syndrome before it became clear
that the ‘‘normal transmitting males,’’ long known to geneticists
as nonpenetrant male carriers of the Fragile X mutation, were
subject to a late age of onset neurodegenerative condition
(Hagerman et al., 2001). Repeated questions from mothers of
fragile X sons regarding their fathers’ symptoms, lead to the
appreciation of a constellation of symptoms that we now refer
to as fragile X tremor ataxia syndrome, or FXTAS (Greco et al.,
2002; Jacquemont et al., 2003). FXTAS can affect both men
and women, but male carriers of the FMR1 premutation are at
significantly greater risk, with more than half exhibiting symp-
toms by age 70 (Jacquemont et al., 2004). Women who carry
the premutation have a much lower risk (less than 20%) (Rodri-
guez-Revenga et al., 2009). While symptoms are variable,
a Parkinsonian tremor and ataxia are common, along with cogni-
tive decline, and mood disorders. Significantly, males with FXS,
who can live to old age, do not commonly develop FXTAS.
Features of FXTAS patients also include unusual findings inNeuron 77, March 6, 2013 ª2013 Elsevier Inc. 833
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cles have increased T2-weighted density) (Jacquemont et al.,
2003), and at autopsy, widespread, large eosinophilic nuclear
inclusions that stain with ubiquitin and proteins involved in pro-
teasome degradation are found in both neurons and glia (Greco
et al., 2006). While the inclusions are reminiscent of findings in
disorders involving polyglutamine expansions, they do not stain
with antibodies that can detect polyglutamine. FXTAS patient’s
brains typically demonstrate mild-to-moderate global atrophy,
most common in the frontal and parietal regions, as well as
in the pons and cerebellum including Purkinje neuron loss,
Bergmann gliosis, spongiosis of the deep cerebellar whitematter
and swollen axons (Greco et al., 2006). Ubiquitin staining nuclear
inclusions and neuronal loss are not commonly found in the
brains of individuals with fragile X syndrome.
Finding nuclear inclusions at autopsy and specific MRI
anomalies helped to distinguish FXTAS as a distinct clinical
entity, different from other neurological conditions of old age.
Importantly, the differences in pathology between FXS and
FXTAS demanded new hypotheses for the contribution of the
FMR1 CGG repeat expansion to the disorder. FXS clearly results
from loss of FMR1 function due to the large expansion muta-
tion’s effect of shutting off transcription of the FMR1 gene. Pre-
mutation alleles were found to express somewhat more FMR1
RNA (Kenneson et al., 2001; Tassone et al., 2000), and since
the repeat expansion was confined to the 50 untranslated region
of the gene, were not expected to qualitatively alter the FMR1
protein. Fortunately, progress in characterizing another trinucle-
otide repeat expansion disorder, myotonic muscular dystrophy
(DM), provided a road map for investigations into FXTAS.
With the identification of expanded and unstable repeats in
FXS and SBMA, several groups hypothesized a similar muta-
tional mechanism for DM, since repeat instability provided
a molecular mechanism to explain the long-debated genetic
peculiarities of this disorder (Sutherland et al., 1991). Myotonic
dystrophy is a common (1/8,000) typically adult-onset muscle
disease involving myotonia and muscle wasting that includes
skeletal, cardiac, and smooth muscle. Numerous other symp-
toms are more variable, including cataracts and central nervous
system involvement. DM pedigrees often show more severe
disease in the younger members of the family. This includes
a severe form of ‘‘congenital’’ DM in children born to affected
mothers that can be fatal (Udd and Krahe, 2012). The term antic-
ipation was coined a century ago to describe the observation of
worsening symptoms in subsequent generations of this domi-
nantly inherited disease. Some geneticists were reluctant to
accept the phenomenon, questioning whether ascertainment
bias in selection of patients was the explanation, since muta-
tions were not known to be variable between generations
(Harper et al., 1992). The examples of FXS and SBMA led to
discovery by several groups of a highly unstable CTG repeat
in the 30 untranslated region of the myotonic dystrophy protein
kinase (DMPK) gene (Brook et al., 1992; Fu et al., 1992; Maha-
devan et al., 1992). This repeat showed instability and size
ranges that nicely explained the anticipation in pedigrees; all
affected members had repeat lengths longer than the range in
the general population, and longer repeats led to more severe
disease, with congenital cases exhibiting very large expansions.834 Neuron 77, March 6, 2013 ª2013 Elsevier Inc.Most significantly, the repeat length tended to increase when
transmitted from parent to child, providing a mechanism for
anticipation: directional hypermutability (Shelbourne and John-
son, 1992).
Themechanism bywhich theDMPK expandedCTG repeat led
to disease pathology was much less clear in 1992, since the
location of the repeat did not predict an altered protein (as in
SBMA) or simple loss of function of DMPK (as in FXS). Several
hypotheses were proposed, including effects of the repeat
expansion on neighboring genes and reduced DMPK levels
due to RNA processing and transport effects. The observations
in 1995 of nuclear foci containing the DMPK transcript in mutant
cells (Taneja et al., 1995), with the subsequent identification of
RNA-binding proteins present in nuclear foci (Mankodi et al.,
2001; Miller et al., 2000) and interacting with the expanded
repeat spurred a third hypothesis where repeat expansion leads
to a toxic gain of function mediated through RNA. Significant
support for this idea stemmed from mouse models, where
CTG expressed in RNA as a transgene outside of the DMPK
context recapitulated many DM features (Mankodi et al., 2000),
while heterozygous loss of DMPK in the mouse showed little
pathology (Reddy et al., 1996). The discovery that DM2, a very
similar autosomal dominant human myotonic dystrophy, re-
sulted from a tetranucleotide (CCTG) repeat expansion in an in-
tronic location of a separate gene (CNBP) (Liquori et al., 2001),
added strong support to the toxic gain of function hypothesis,
although there remain aspects of the DM1 phenotype that may
result from other effects on the DMPK locus. For example,
knockout of DMPK in the mouse can cause cardiac abnormali-
ties that are reminiscent of those in DM patients (Berul et al.,
1999). Importantly, repeat sequence-mediated RNA toxicity is
especially attractive for explaining the correlation of repeat
length with disease severity. Longer repeats might be expected
to have a more pronounced effect on cellular metabolism, with
the possibility of differential susceptibility among tissues altering
the onset and constellation of symptoms. Mouse and Drosophila
models expressing RNAs containing the expanded CUG repeats
in untranslated regions unrelated to DMPK have also provided
demonstration of toxicity (de Haro et al., 2006; Mankodi et al.,
2000).
The toxic gain of function that results from the DM1 and DM2
repeat expansions appears to be mediated in part through
abnormal interactions of the respective RNAs with proteins
controlling RNA metabolism. Skeletal and cardiac muscle have
been the primary sites of investigation due to the presence of
myotonia in most patients. RNA binding proteins with an affinity
for CUG repeats (CELF1 and 2) (Timchenko et al., 1996) and
human muscleblind proteins (MBNL1–3) (Wang et al., 2012)
have received considerable attention; their typical develop-
mental changes in abundance are modified in the presence of
the expanded CUG repeat containing RNA (Fardaei et al.,
2001; Lin et al., 2006; Mankodi et al., 2001; Timchenko et al.,
2001). This in turn results in changes to the developmentally
regulated patterns of alternative splicing of numerous RNA
targets in muscle (Kalsotra et al., 2008). Modulating the levels
of these RNA binding proteins in mouse models can mimic these
changes, and result in similar pathology (Kanadia et al., 2003) or
rescue (Kanadia et al., 2006; Charizanis et al., 2012). Echeverria
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effects of the CUG and CCUG expansions on RNA binding
proteins. Some downstream effects of the alterations in mRNA
metabolism have been described. A particularly striking example
is altered splicing resulting from reduced MBNL1 levels that
leads to reduced levels of the chloride channel CLCN1 in both
mouse models and skeletal muscle of patients. The character-
istic myotonia of DM results from CLCN1 reduction, and can
be rescued by overexpression of MBNL1 (Kanadia et al., 2003,
2006).
Many challenges remain for understanding the various effects
of the expanded CUG sequences expressed in patients with
myotonic dystrophy. The behavioral and cognitive aspects of
the disorder have received significant attention, and there has
been some exciting progress showing alterations in differen-
tiated embryonic stem cells demonstrating neurite path finding
defects (Marteyn et al., 2011). It is clear that many transcripts
are affected at a variety of levels (Du et al., 2010) and that a large
fraction of the observed effects on protein and RNA abundance
may be secondary to the primary disruption by the repeat-
containing RNA.
The findings that the expanded CUG repeat expressed in RNA
is likely to be the principal agent of cellular damage in myotonic
dystrophy and that haploinsufficiency of DMPK is not highly
pathogenic allows consideration of therapeutic strategies that
target the RNA directly. Mahadevan et al. (2006) demonstrated
in an inducible DMPK overexpression model in the mouse that
DM muscle phenotypes were reversed after shutting off expres-
sion, suggesting that damage in muscle was not permanent. A
number of recent studies have targeted the DMPK mRNA
expanded CUG repeat with the aim of disassociating interacting
proteins. Antisense oligonucleotides (Mulders et al., 2009;
Wheeler et al., 2009; Franc¸ois et al., 2011; Lee et al., 2012), small
peptides (Garcı´a-Lo´pez et al., 2011), or small molecules (Childs-
Disney et al., 2012a, 2012b; Parkesh et al., 2012; Warf et al.,
2009) have targeted the CUG sequence to disrupt binding or
destroy the mutant RNA and have shown significant efficacy in
modifying downstream effects. Mahadevan (2012) argues that
it might be best to destroy the expanded RNA, since displacing
its protein partners and eliminating RNA foci still leaves the RNA
available for other possible mischief. The Cooper and Thornton
groups recently describe methods to utilize gapmer oligonucle-
otides to induce RNaseH cleavage in the nucleus of muscle of
a transgenic DM1 mouse model (Wheeler et al., 2012; Lee
et al., 2012). Numerous features of the disease were corrected
long term.
While evidence for a significant role for the expanded repeat
carrying RNA in DM is quite persuasive, recent observations
regarding the potential for expanded repeats leading to unusual
protein translation offers another hypothesis regarding toxic
agents. Ranum and colleagues have proposed the term
repeat-associated non-ATG (RAN) translation to describe the
process encoding homopolymeric polyproteins from RNAs
containing triplet repeats (Zu et al., 2011). These appear to
play a role in the pathology in SCA8 (Moseley et al., 2006), and
there may be polyglutamine peptides produced from the
expanded DMPK allele. This phenomenon deserves attention
for all of the repeat-associated disorders that involve toxic RNA.The effort to understand the toxic nature of the noncoding
CTG repeat expansion in DM1 and the intronic CCTG repeat
expansion in DM2 provided considerable guidance for studying
the potential pathogenic mechanisms in FXTAS. The expanded
CGG repeat transcribed into mRNA in premutation carriers
likely caused pathology, especially since it was not expressed
in individuals with FXS, who showed no FXTAS symptoms.
While the higher than normal levels of FMR1 mRNA (Kenneson
et al., 2001; Tassone et al., 2000) could play a role, the ex-
panded repeat’s enhanced ability to interact with RNA-binding
proteins similarly with the DM1 mRNA was the main suspect.
Jin and colleagues provided evidence that the expanded
CGG in a transcript unrelated to FMR1 in a Drosophila model
could cause a similar neurodegeneration to that seen in
patients, including the presence of ubiquitin-positive nuclear
inclusions (Jin et al., 2003). This observation strongly implicated
the repeats, and subsequent work using the same model
provided evidence for a role for RNA-binding proteins in modu-
lating the phenotype (Jin et al., 2007; Sofola et al., 2007). Inter-
estingly, one of these proteins, CELF1, also played a role in
DM1 pathology, while others, PURA and HNRNPA2B1 have
not been implicated. Both PURA and HNRNPA2B1 were found
to bind CGG repeats in RNA, while CELF1 binds in conjunction
with HNRNPA2B1.
Efforts to model the premutation associated disorder in the
mouse were accelerated by existing knockin models for CGG
repeat expansion that had been developed to characterize the
instability of the repeat (Bontekoe et al., 1997; Lavedan et al.,
1998). The model developed by Oostra and colleagues accumu-
lated nuclear inclusionswith age similarly with FXTAS (Willemsen
et al., 2003), as well as behavioral and other features that corre-
late with the human syndrome (Brouwer et al., 2008; Van Dam
et al., 2005). A limitation with the model is that animals begin to
show phenotypes after six months, increasing analysis times.
Hashemand colleagues developed transgenicmice that express
mRNAs with 90 untranslated CGG repeats in both FMR1 and
enhanced green fluorescent protein contexts specifically in
Purkinje neurons, observing nuclear inclusions, cell death, and
behavioral deficits (Hashem et al., 2009). These mice provided
evidence in a mammalian model that expressed CGG repeats
were both necessary and sufficient to cause in neurodegenera-
tion. This model also develops phenotypes more rapidly,
providing for faster analyses and improved surveys of modifying
genes and treatments.
A hallmark feature of FXTAS is the presence of ubiquitin-
stained nuclear inclusions. These are also found in fly andmouse
models. They are large and typically only one is found per
nucleus. They stain with antibodies to a variety of proteins with
chaperone and proteolysis functions (e.g., HSP70, 20s subunit
of the proteosome) (Iwahashi et al., 2006), and resemble inclu-
sions found in polyglutamine disorders, but do not stain with
anti-polyglutamine antibodies. As in DM1, CGG-repeat contain-
ing RNA can be found in the inclusions (Sellier et al., 2010;
Tassone et al., 2004), and it is likely that as the RNA seeds accu-
mulation of proteins into the inclusion, it alters these proteins’
abundance or localization, leading to events that can be toxic
to the cell. Unlike DM1, the bulk of the mutant RNA is not located
in the inclusion, since FMR1mRNA is translated and there is littleNeuron 77, March 6, 2013 ª2013 Elsevier Inc. 835
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neson et al., 2001; Tassone et al., 2000). Interestingly, reduced
FMRP is found in brains of mice with large CGG repeat expan-
sions (Iliff et al., 2013). While evidence for similar premutation-
associated changes in brains of individuals with FXTAS is
lacking, these men do not exhibit cognitive difficulties prior to
onset of the disorder later in life, suggesting that any reduction
in protein levels that may be present does not affect intelligence.
It remains unclear whether the inclusions represent a toxic entity
or clearance of the toxic RNA. Interest in the components of the
inclusion led to their purification from human autopsy material
with subsequent identification of proteolysis products with
mass spectroscopy (Iwahashi et al., 2006). A large number of
additional proteins were found, including histones, intermediate
filaments, microtubules, myelin associated proteins and RNA
binding proteins HNRNPA2B1 and MBNL1.
Sellier and colleagues described sequestration of SAM68 into
nuclear inclusions in cells transfected with CGG expressing
transgenes and subsequently in a mouse FXTAS model and in
human samples (Sellier et al., 2010). They propose that SAM68
is required for MBNL1 and HNRNPG association in the inclu-
sions. SAM68 is an RNA-binding protein with a role in control
of alternative splicing, and they show changes to SAM68 targets’
splicing patterns in patients. PURA is one of the RNA-binding
proteins that interact with expanded CGGs in RNA, can be found
in the inclusions in patients, and modifies phenotypes in the
Drosophila model (Jin et al., 2007). Mice lacking PURA are
born without symptoms but rapidly develop severe tremor and
seizures (Hokkanen et al., 2012; Khalili et al., 2003). Qurashi
and colleagues defined more than 100 proteins that interact
with PURA in Drosophila, including FMRP (Qurashi et al.,
2011). Among these is Rm62, which shows reduced levels in
the presence of expanded CGG transcripts, with subsequent
nuclear accumulation of mRNA encoding Hsp70 and other
stress response transcripts. It appears likely that FXTAS, like
DM1 and DM2, results at least partially from changes in patterns
of alternative RNA splicing, transport and translation driven by
quantitative changes in RNA-binding proteins.
Therapeutic intervention strategies for FXTAS are following the
paths defined for DM1, although with the much larger challenge
of targeting neurons instead of muscle. Already, small molecules
that disrupt CGG structure are in development (Disney et al.,
2012), and show efficacy in cell culture models. A drug screen
utilizing the Drosophila model has provided small molecules
that reduce the neurodegeneration phenotype (Qurashi et al.,
2012). Among these are phospholipase A(2) inhibitors, which
may have promise for treatment. FXTAS mouse models will
provide data on the ability of these compounds to alter the
course of FXTAS phenotypes.
The myotonic dystrophies and FXTAS demonstrate that
expanded microsatellites expressed in RNA can have toxic
effects. Several other neurodegenerative disorders resulting
from non-coding trinucleotide repeat expansions appear to
have similar mechanisms, including SCA8 and HDL2. Antisense
transcripts in many of the disease loci provide additional possi-
bilities, and it remains possible that aspects of the coding-
sequence repeat expansion disorders result from toxic RNA
(Tan et al., 2012). Additional enlarged microsatellites expressed836 Neuron 77, March 6, 2013 ª2013 Elsevier Inc.in RNA appear capable of inducing neurodegeneration.
Examples include ATTCT repeat expansion in SCA10 (Matsuura
et al., 2000), GGCCTG repeat expansion in SCA36 (Kobayashi
et al., 2011) and GGGGCC repeat expansion in a common domi-
nant familial form of amyotrophic lateral sclerosis and frontotem-
poral dementia (DeJesus-Hernandez et al., 2011; Renton et al.,
2011). As more examples of transcribed polymorphic microsa-
tellites conferring pathology are uncovered, and as it becomes
clear that a large fraction of the genome is transcribed into
RNA, it might be of interest to investigate the role of this mecha-
nism in variable susceptibility to more common disorders. For
example, is there a liability from numerous loci with small expan-
sions that is similar to a single locus with a large expansion?
Further advances in genome sequencing will be required to
capture long repeated sequences, which have been more diffi-
cult to accurately determine using current high-throughput
methods.
Closing Comments
Clearly one of the seminal developments in human genetics is
the identification of the expansion of unstable nucleotide repeats
as a mutational mechanism. In addition to providing the molec-
ular basis for several devastating neurological disorders, study
of the unstable microsatellite repeat disorders described in this
review also provided insight into very basic aspects of neurosci-
ence. For example, understanding the function of FMRPwas key
in appreciating the importance local mRNA translation plays in
regulating synaptic function. Both FXS and FXTAS/DMs also
played significant roles in understanding pathways by which
RNA-binding proteins regulate RNA processing, and thereby
neuronal function and development. Work on SCA1 indicates
there is an overlap between development and degeneration.
The eventual timing of the onset of degeneration at later ages
may actually be determined during early development. Thus,
we should be cautious in thinking of neural development and
age-dependent degeneration as discrete entities. Progress
made over the first two decades of research on these unstable
microsatellite disorders provides solid platforms from which
hopefully effective treatments will emanate over the next several
years.
We can draw important inferences from the disorders
described here, largely due to expansions of trinucleotide
repeats, for elucidating the mechanisms by which expansions
in other recently identified dynamic mutations lead to disease
pathology, e.g., the C9ORF92 hexanucleotide repeat in ALS
and FTLD, and pentanucleotide repeats associated with
SCA10 and SCA31. First, a detailed characterization of the
disease in patients is critical. Is it inherited in a dominant or
recessive fashion? If recessive, do mutation carriers have an
altered phenotype? Understanding where the repeat is located
relative to surrounding genes is vital for appreciating whether
expansion leads to a simple loss of function as in FXS, or a toxic
RNA as in FXTAS and DM. Thus, the intronic location of
the unstable microsatellite repeats in C9ORF92, SCA10 and
SCA31 are suggestive of either a toxic RNA as in FXTAS and
DM or a loss of expression as seen in Friedreich’s ataxia.
The recent report of non-ATG-mediated translation from the
repeat containing RNA raises the possibility that toxic peptides
Neuron
Reviewalso contribute to disease and recent evidence from study of
C9ORF72 showing that dipeptide-repeat proteins are produced
from the expanded hexanucleotide repeat and aggregate (Mori
et al., 2013; Ash et al., 2013) suggests there may be a role for
protein toxicity in this disorder. While an expandedmicrosatellite
can have many molecular outcomes, the key is to find those that
have a substantive contribution to disease. Research highlighted
here demonstrates the importance of applying a cross-species
spectrum of animal models from invertebrates to mammals in
revealing and testing pathways fundamental to pathogenesis.
Identification of mechanisms that are fundamental for dysfunc-
tion and degeneration of affected neural systems maximizes
the likelihood of developing effective therapeutic approaches.ACKNOWLEDGMENTS
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